{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:40:38Z","timestamp":1788871238451,"version":"build-2803163510"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T00:00:00Z","timestamp":1388707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["C23591452"],"award-info":[{"award-number":["C23591452"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>The Janus kinase inhibitor tofacitinib is currently being investigated as a disease-modifying agent in rheumatoid arthritis (RA). We investigated the in-vivo effects of tofacitinib treatment for 4 weeks on elevated circulating acute-phase serum amyloid (SAA) levels in 14 Japanese patients with RA. SAA levels fell from 110\u00b75 \u00b1 118\u00b75 \u03bcg\/ml (mean \u00b1 standard deviation) at treatment initiation to 15\u00b73 \u00b1 13\u00b73 \u03bcg\/ml after 4 weeks treatment with tofacitinib. The reduction in SAA levels was greater in patients receiving tofacitinib plus methotrexate compared with those receiving tofacitinib monotherapy. Tofacitinib was also associated with reduced serum interleukin (IL)-6, but had no effect on serum levels of soluble IL-6 receptor. Patients were divided into groups with adequate (normalization) and inadequate SAA responses (without normalization). Serum IL-6 levels were reduced more in the group with adequate SAA response compared with those with inadequate SAA response. These results suggest that tofacitinib down-regulates the proinflammatory cytokine, IL-6, accompanied by reduced serum SAA levels in patients with active RA. The ability to regulate elevated serum IL-6 and SAA levels may explain the anti-inflammatory activity of tofacitinib.<\/jats:p>","DOI":"10.1111\/cei.12234","type":"journal-article","created":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T07:52:36Z","timestamp":1383810756000},"page":"208-214","source":"Crossref","is-referenced-by-count":60,"title":["Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis"],"prefix":"10.1093","volume":"175","author":[{"given":"K","family":"Migita","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Jiuchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kozuru","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Nagasaki Medical Center, Omura, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Nagasaki Medical Center, Omura, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Motokawa","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Nagasaki Medical Center, Omura, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shinto Kumamoto Hospital, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,1,3]]},"reference":[{"key":"2021111804104916200_cei12234-bib-0001","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"2021111804104916200_cei12234-bib-0002","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"2021111804104916200_cei12234-bib-0003","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/BOR.0b013e3283454124","article-title":"New therapies in the management of rheumatoid arthritis","volume":"23","author":"Buch","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"2021111804104916200_cei12234-bib-0004","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrrheum.2013.8","article-title":"The problem of choice: current biologic agents and future prospects in RA","volume":"9","author":"Choy","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"2021111804104916200_cei12234-bib-0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00644.x","article-title":"Therapeutic targeting of Janus kinases","volume":"223","author":"Pesu","year":"2008","journal-title":"Immunol Rev"},{"key":"2021111804104916200_cei12234-bib-0006","doi-asserted-by":"crossref","first-page":"i70","DOI":"10.1136\/annrheumdis-2011-200595","article-title":"In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis","volume":"71","author":"Tanaka","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021111804104916200_cei12234-bib-0007","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021111804104916200_cei12234-bib-0008","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/ard.2009.108159","article-title":"Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial","volume":"69","author":"Coombs","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021111804104916200_cei12234-bib-0009","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"2021111804104916200_cei12234-bib-0010","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","article-title":"A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone","volume":"64","author":"Kremer","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021111804104916200_cei12234-bib-0011","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021111804104916200_cei12234-bib-0012","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2362.1996.159291.x","article-title":"Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice","volume":"26","author":"Malle","year":"1996","journal-title":"Eur J Clin Invest"},{"key":"2021111804104916200_cei12234-bib-0013","first-page":"58","article-title":"Serum amyloid A in the assessment of early inflammatory arthritis","volume":"27","author":"Cunnane","year":"2000","journal-title":"J Rheumatol"},{"key":"2021111804104916200_cei12234-bib-0014","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/art.22118","article-title":"Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis","volume":"54","author":"Okuda","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021111804104916200_cei12234-bib-0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"2021111804104916200_cei12234-bib-0016","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2443.2005.00900.x","article-title":"Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression","volume":"10","author":"Hagihara","year":"2005","journal-title":"Genes Cells"},{"key":"2021111804104916200_cei12234-bib-0017","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3899\/jrheum.101362","article-title":"Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium","volume":"38","author":"Migita","year":"2011","journal-title":"J Rheumatol"},{"key":"2021111804104916200_cei12234-bib-0018","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar3333","article-title":"CP690,550 inhibits oncostatin M-induced JAK\/STAT signaling pathway in rheumatoid synoviocytes","volume":"13","author":"Migita","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2021111804104916200_cei12234-bib-0019","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bbrc.2003.12.096","article-title":"IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system","volume":"314","author":"Hagihara","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"2021111804104916200_cei12234-bib-0020","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/art.33455","article-title":"Acute-phase serum amyloid A regulates tumor necrosis factor \u03b1 and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy","volume":"64","author":"Connolly","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021111804104916200_cei12234-bib-0021","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/ard.54.8.674","article-title":"Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study","volume":"54","author":"van Leeuwen","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"2021111804104916200_cei12234-bib-0022","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3899\/jrheum.121389","article-title":"Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis","volume":"40","author":"Shimamoto","year":"2013","journal-title":"J Rheumatol"},{"key":"2021111804104916200_cei12234-bib-0023","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"2021111804104916200_cei12234-bib-0024","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1186\/ar4162","article-title":"Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6\/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes","volume":"15","author":"Choe","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2021111804104916200_cei12234-bib-0025","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/ard.2011.150284","article-title":"The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon","volume":"71","author":"Rosengren","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021111804104916200_cei12234-bib-0026","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/annrheumdis-2012-202470","article-title":"Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement","volume":"72","author":"Schoels","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021111804104916200_cei12234-bib-0027","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.34329","article-title":"The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-\u03b3 and interleukin-17 production by human CD4+ T cells","volume":"64","author":"Maeshima","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021111804104916200_cei12234-bib-0028","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/art.37691","article-title":"Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors","volume":"64","author":"Yarilina","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021111804104916200_cei12234-bib-0029","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/art.27536","article-title":"Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice","volume":"62","author":"Lin","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12234","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/175\/2\/208\/41083484\/cei12234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/175\/2\/208\/41083484\/cei12234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T11:25:27Z","timestamp":1641036327000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/175\/2\/208\/6378171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,3]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,1,3]]},"published-print":{"date-parts":[[2014,1,3]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12234","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,2]]},"published":{"date-parts":[[2014,1,3]]}}}